Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05401578 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Canakinumab for the Treatment of Postprandial Hypoglycemia

Study acronym: CanpHy
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 29, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revised at 2 of 2 sitesv6
  2. Primary and study completion dates: May 2024 to May 31, 2026v5
  3. Start date changed from estimate of Feb 1, 2023 to Apr 17, 2023v4
  4. Start date: Sep 2022 to Feb 1, 2023v3
  5. Start date: Jun 2022 to Sep 2022v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this randomized trial is to test whether a treatment with canakinumab is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.
Trial Details
NCT Number NCT05401578
Lead Sponsor University Hospital, Basel, Switzerland
Conditions
(from sponsor)		 Postprandial Hypoglycemia
Related terms Hypoglycemia
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov